Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + zanubrutinib + rituximab + lenalidomide + prednisone
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This is a combination therapy consisting of five agents: polatuzumab vedotin (an antibody-drug conjugate targeting CD79b), zanubrutinib (a Bruton's tyrosine kinase inhibitor), rituximab (an anti-CD20 monoclonal antibody), lenalidomide (an immunomodulatory drug), and prednisone (a corticosteroid). While combinations of polatuzumab vedotin, zanubrutinib, and rituximab (ZPR) have been studied in diffuse large B-cell lymphoma (DLBCL), particularly in relapsed/refractory cases and in elderly or frail patients, the specific five-drug combination including lenalidomide and prednisone is not well-documented in the current literature.
02
Targets
CD20 (B-lymphocyte antigen CD20)B-cell antigen receptor complex-associated protein beta chainCRBN (Cereblon)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on polatuzumab vedotin + zanubrutinib + rituximab + lenalidomide + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + zanubrutinib + rituximab + lenalidomide + prednisone.